IL6 and COVID-19: The latter might be the reason behind the controversies surrounding tocilizumab efficacy in treating COVID-19 as it has been thought that the ongoing replication of the virus overwhelms the drug capacity to control the disease burden.[25] Therefore, adding colchicine to IL-6 antagonists with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm and therefore the need for invasive mechanical ventilation and eventually death.